INTERET D'UN TRAITEMENT COMBINE ASSOCIANT CHIMIOTHERAPIE INTRA-ARTERIELLE HEPATIQUE ET CHIMIOTHERAPIE SYSTEMIQUE DANS LES METASTASES HEPATIQUES DES ADENOCARCINOMES COLORECTAUX

PARIS6-Bibl. St Antoine CHU (751122104) / SudocPARIS-BIUM (751062103) / SudocSudocFranceF

Effects of cold post-harvest treatments of sweet bell peppers on the development of the Mediterranean fruit fly (Ceratitis capitata)

We investigated the survival of Mediterranean fruit fly (Medfly) larval stages on yellow peppers stored for 21 d in cold environments (1.5, 4 and 7 °C), and the differences in larval mortality rates of Medflies exposed to 1.5 °C storage environments between yellow and red peppers. In addition, we investigated the effect of packing yellow peppers and exposing them to cold environments for 21 d on the quality of the fruits. The aim of the study was to investigate packing and shipping post-harvest protocols as a preliminary investigation to explore cold environments as a system to assure the export of quality peppers with low risks of surviving Medfly immature stages. This exploratory study showed that storing yellow peppers for 21 d in lined boxes (20-μm-thick macroperforated Xtend film) at 1.5 and 4 °C protected the quality of the fruit, and precluded the survival of Medfly eggs and larval stages (L1, L2 and L3). In contrast, peppers stored at 7 °C for 21 d did not completely kill immature stages of the Medfly. In addition, the study showed that Medfly larval stages exposed to 1.5 °C environments on yellow and red peppers have different tolerances to cold. Sensitivity to cold in red pepper was higher than in yellow for all larval stages. In addition, sensitivity to cold between larval stages varied between yellow and red peppers: for yellow, sensitivity preceded as follows L1 > L2 > L3, while in red peppers it was L2 > L1 > L3. Abilities to accumulate lipids and protein by feeding Medfly larvae suggest that palatability and nutrition may be partially responsible for the differences in cold tolerance.7 page(s

A phase II single-arm study of irinotecan in combination with temozolomide (TEMIRI) in children with newly diagnosed high grade glioma: a joint ITCC and SIOPE-brain tumour study

A multicenter, two stage phase II study, investigated irinotecan plus temozolomide in children with newly diagnosed high grade glioma. The primary endpoint was tumor response during a two-cycle treatment window, confirmed by external review committee. Patients received oral temozolomide 100 mg/(m 2 day) (days 1-5) and intravenous irinotecan 10 mg/(m2 day) (days 1-5 and 8-12) for two 21-day cycles (three cycles for patients exhibiting objective tumor response). Standard treatment was then administered according to local investigator choice. In total 17 patients were enrolled and treated by local investigators. However, central pathology review found three patients did not have a diagnosis of high grade glioma and another four patients did not have evaluable disease according to independent central radiological review. The primary endpoint was based on the first ten evaluable patients as determined by the external review committee. Recruitment was stopped for futility after there were no complete or partial responses during the two-cycle treatment window in the first ten evaluable patients. Five patients had stable disease, and five progressed. Data for secondary endpoints including; time to tumor progression, time to treatment failure, and overall survival is reported. The safety profile of the treatment showed the combination was tolerable with two patients (11.8 %) having grade three nausea, and one (5.9 %) experiencing a grade four neutropenia, leading to permanent discontinuation from adjuvant treatment. Irinotecan plus temozolomide, although well tolerated did not improve outcome over historical controls in this setting. © 2013 Springer Science+Business Media New York